OpenSecrets.org @OpenSecretsDC
Psychedelic drug development company Cybin recruited extra muscle to help navigate the regulatory process as it readies a clinical trial on its sublingual formulation of psilocybin for patients with major depressive disorder https://t.co/Vc3I7FRNOV — PolitiTweet.org